Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
NCT ID NCT07748260
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether giving four cycles of chemotherapy combined with targeted therapy (trastuzumab and pertuzumab) before surgery works as well as the standard six cycles for people with intermediate-risk HER2-positive breast cancer. The goal is to see if a shorter treatment can reduce side effects without compromising the chance of eliminating the tumor. The study will compare the rates of complete tumor disappearance between the two treatment groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of chemotherapy (taxane) plus two targeted antibodies, trastuzumab and pertuzumab, given for either 4 or 6 cycles before surgery.
- What this could lead to
- If successful, this could show that many patients with intermediate-risk HER2-positive breast cancer can receive fewer chemotherapy cycles, reducing side effects while maintaining treatment effectiveness.
- What could go wrong
- The trial is still in progress, and it is not yet known if the shorter treatment will be as effective as the longer one. There is also a risk that reducing chemotherapy could lead to higher rates of residual cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?
- Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer